Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Richard Giroux, Chief Financial Officer and Chief Operating Officer of MeiraGTx Holdings PLC (NASDAQ:MGTX), sold 24,000 ordinary shares of the company on July 22, 2025, according to a recent SEC filing. The shares were sold at a weighted average price of $8.52, for a total transaction value of $204,480. The sale comes as MGTX trades near its 52-week high of $8.98, having delivered an impressive 80% return over the past year.
The sales were executed in multiple transactions with prices ranging from $8.38 to $8.61. This transaction was executed under a pre-arranged 10b5-1 trading plan that Giroux adopted on August 29, 2024. Following the sale, Giroux directly owns 853,494 ordinary shares of MeiraGTx. According to InvestingPro analysis, the stock’s technical indicators suggest overbought conditions, with 13 additional real-time insights available to subscribers.
Additionally, the filing indicates that Giroux indirectly owns 5,152 shares through a spouse and 85,000 shares through Aigle Healthcare Partners III LLC. The company currently maintains a market capitalization of $689.5 million.
In other recent news, MeiraGTx Holdings plc has received all necessary clearances under the United Kingdom (TADAWUL:4280)’s foreign direct investment laws for its proposed transactions with Hologen Limited. These transactions, initially agreed upon in March 2025, are expected to conclude in July 2025. The company announced this development through a filing with the U.S. Securities and Exchange Commission, although specific details about the transactions were not disclosed. Additionally, the U.S. Food and Drug Administration (FDA) has granted MeiraGTx’s gene therapy product AAV-GAD Regenerative Medicine Advanced Therapy (RMAT) designation. This designation aims to expedite the development and review of promising therapies for serious conditions. The RMAT status was awarded based on positive outcomes from three clinical studies, highlighting AAV-GAD’s potential benefits for Parkinson’s disease patients. These recent developments underscore MeiraGTx’s ongoing efforts in advancing its genetic medicines pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.